Chengdu Kanghua Biological Products

Moderna and Merck announced preliminary positive results from the Phase III clinical trial of their mRNA personalized cancer vaccine, intismeran autogene, igniting the A-share pharmaceutical sector. On the morning of August 20, multiple vaccine stocks including Baike Biotech, Walvax Biotechnology, CanSino Biologics, Kanghua Biologics, Laimei Pharmaceutical, and Novoprotein hit the 20% daily limit, while Hong Kong-listed CanSino Biologics and Everest Medicines surged over 50% intraday. The vaccine, combined with Keytruda, was used as adjuvant therapy in more than 1,100 high-risk melanoma patients after complete surgical resection, achieving key endpoints of recurrence-free survival and reduced risk of distant metastasis. Following the announcement, Moderna's stock price soared nearly 180%, while Merck's rose over 12%.

Kanghua Biological released its 2026 interim report, with net profit attributable to the parent company of 141 million yuan, up 23.25% from the same period last year. Total operating revenue was 538 million yuan, up 11.25% year on year. Net cash inflow from operating activities was 161 million yuan, up 147.23% year on year. The company's latest asset-liability ratio was 8.99%, gross margin was 89.76%, and diluted earnings per share was 1.09 yuan.